- Home
- IONS vs ELF Comparison
IONS vs ELF Comparison
Compare IONS & ELF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- ELF
- Stock Information
- Founded
- IONS 1989
- ELF 2004
- Country
- IONS United States
- ELF United States
- Employees
- IONS N/A
- ELF N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- ELF Package Goods/Cosmetics
- Sector
- IONS Health Care
- ELF Consumer Discretionary
- Exchange
- IONS Nasdaq
- ELF Nasdaq
- Market Cap
- IONS 6.8B
- ELF 7.2B
- IPO Year
- IONS 1991
- ELF 2016
- Fundamental
- Price
- IONS $70.41
- ELF $123.23
- Analyst Decision
- IONS Strong Buy
- ELF Strong Buy
- Analyst Count
- IONS 20
- ELF 15
- Target Price
- IONS $75.55
- ELF $141.40
- AVG Volume (30 Days)
- IONS 2.1M
- ELF 1.4M
- Earning Date
- IONS 10-29-2025
- ELF 11-05-2025
- Dividend Yield
- IONS N/A
- ELF N/A
- EPS Growth
- IONS N/A
- ELF N/A
- EPS
- IONS N/A
- ELF 1.69
- Revenue
- IONS $944,050,000.00
- ELF $1,342,779,000.00
- Revenue This Year
- IONS $24.02
- ELF $26.84
- Revenue Next Year
- IONS $4.06
- ELF $18.01
- P/E Ratio
- IONS N/A
- ELF $72.81
- Revenue Growth
- IONS 16.05
- ELF 18.61
- 52 Week Low
- IONS $23.95
- ELF $49.40
- 52 Week High
- IONS $74.42
- ELF $150.99
- Technical
- Relative Strength Index (RSI)
- IONS 63.48
- ELF 39.53
- Support Level
- IONS $70.47
- ELF $122.53
- Resistance Level
- IONS $74.42
- ELF $141.50
- Average True Range (ATR)
- IONS 1.84
- ELF 6.84
- MACD
- IONS -0.64
- ELF -1.98
- Stochastic Oscillator
- IONS 37.12
- ELF 2.77
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About ELF e.l.f. Beauty Inc.
e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.